Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS
No-Receipt date
2020-04649 - 07/12/2020
No-Filing date
20200403400 - 07/12/2020
No-Granting date
3105783 - 22/12/2020
No-EPO application date
15759254.4 - 09/03/2015
No-EPO granting date
3113772 - 09/09/2020
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
12/2020 - 19/01/2021
Expiration date
10/03/2035
Kind of title
Validation of European Patent
Legal status
VALID
Priorities
US201461949808 P07/03/2014/US
US201461981515 P18/04/2014/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
C07D 417/12
C07D 413/12
C07D 413/04
C07D 405/12
C07D 403/12
C07D 403/04
C07D 401/14
C07D 401/04
C07D 231/14
A61P 7/02
A61K 31/415
Related Documents
Related Titles
Type
Master title
Related title
[SPC]
20210800035
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
1237071
BIOCRYST PHARMACEUTICALS, INC.
4505 EMPEROR BLVD.
DURHAM, NORTH CAROLINA 27703
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
3153826
KOTIAN, PRAVIN L.
3153827
BABU, YARLAGADDA S.
3153828
WU, MINWAN
3153829
CHINTAREDDY, VENKAT R.
3153830
KUMAR, SATISH V.
3153831
ZHANG, WEIHE
Representatives
Code
Firstname
Surname
Address
Town
Zip
3178
STEFANOS ALEXIOS
TSIMIKALIS "TSIMIKALIS KALONAROU DIKIGORIKI ETAIREIA"
NEOFYTOU VAMVA 1
ATHINA (ATTIKIS)
10674
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
8126
STEFANOS ALEXIOS
TSIMIKALIS
NEOFYTOU VAMVA 1
ATHINA (ATTIKIS)
10674
GREECE
Owners History
Title Instruments
Payments history
11 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).